Effect of Limosilactobacillus reuteri Probiotic on Oral Mucositis in Patients Undergoing Head and Neck Radiation: A Randomised Trial
Oral Diseases · 2026-02 · 32 (2) · 480-491
DOI: 10.1111/odi.70083 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Oral Diseases, online erschienen am 31.08.2025. Verfasst von Charlene Enhui Goh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Dentistry, National University of Singapore, Singapore City, Singapore. Hauptthemen laut MEDLINE: Probiotics, Limosilactobacillus reuteri, Stomatitis, Head and Neck Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National University Health System, Ministry of Education - Singapore, Pharmaforte Singapore Pte. Ltd..
Abstract (Originalsprache)
Objective
Limited management strategies exist for cancer therapy‐induced oral mucositis (OM). Materials and Methods We conducted a randomised, double‐blind, placebo‐controlled trial to assess the efficacy and safety of Limosilactobacillus reuteri (LR) probiotic to prevent and reduce the severity of OM in head and neck cancer patients undergoing radiotherapy (RT). Patients ≥ 21 years requiring head and neck RT of ≥ 60 Gy and those undergoing concurrent chemotherapy with RT (CCRT) with no prior OM were recruited. OM incidence and severity were assessed weekly from baseline to two weeks post‐RT. Oral samples were collected at baseline and study mid‐point to profile microbiome changes.
Results
Overall, no significant differences in OM incidence or severity (grade ≥ 3) were observed between LR and placebo groups. However, subgroup analyses of participants who received RT‐only showed significantly lower mean OM scores (−0.42; 95% CI: −0.75, −0.09; p = 0.02) over time in the LR probiotic group. Beta diversity of the oral microbiome was significantly different between the RT‐only probiotic and placebo groups (PERMANOVA: F = 1.77; R 2 = 0.07; p = 0.025). No serious adverse effects were observed in the LR group.
Conclusion
LR probiotic use was safe and associated with a reduced OM incidence and severity in RT‐only participants. These findings are promising and provide important insights for future studies in larger cohorts. Trial Registration ClinicalTrials.gov : NCT03552458
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Dentistry, National University of Singapore, Singapore City, Singapore.
- Singapore Centre for Environmental Life Sciences Engineering, National University of Singapore, Singapore, Singapore.
- Department of Radiation Oncology, National University Cancer Institute, Singapore City, Singapore.
ORCID-Profile: Charlene Enhui Goh, Nitasha Gupta, Kai Soo Tan
Förderung
- National University Health System
- Ministry of Education - Singapore
- Pharmaforte Singapore Pte. Ltd.
Zitieren
APA
Goh, C. E., Williams, R., Gupta, N., Ho, F., Islam, I., Lai, C. W. M., Tan, K. S., & Hong, C. H. L. (2026). Effect of Limosilactobacillus reuteri Probiotic on Oral Mucositis in Patients Undergoing Head and Neck Radiation: A Randomised Trial. Oral Diseases, 32(2), 480-491. https://doi.org/10.1111/odi.70083
Vancouver
Goh CE, Williams R, Gupta N, Ho F, Islam I, Lai CWM, et al. Effect of Limosilactobacillus reuteri Probiotic on Oral Mucositis in Patients Undergoing Head and Neck Radiation: A Randomised Trial. Oral Diseases. 2026;32(2):480-491. doi:10.1111/odi.70083
BibTeX
@article{Goh2026,
author = {Goh, Charlene Enhui and Williams, Rohan and Gupta, Nitasha and Ho, Francis and Islam, Intekhab and Lai, Clement Wei Ming and Tan, Kai Soo and Hong, Catherine Hsu Ling},
title = {Effect of Limosilactobacillus reuteri Probiotic on Oral Mucositis in Patients Undergoing Head and Neck Radiation: A Randomised Trial},
journal = {Oral Diseases},
year = {2026},
volume = {32},
number = {2},
pages = {480--491},
doi = {10.1111/odi.70083}
}
EUVIMED